WAVE Life Sciences Ltd
NASDAQ:WVE

Watchlist Manager
WAVE Life Sciences Ltd Logo
WAVE Life Sciences Ltd
NASDAQ:WVE
Watchlist
Price: 6.03 USD -9.19% Market Closed
Market Cap: 925.5m USD

WAVE Life Sciences Ltd
Investor Relations

WAVE Life Sciences Ltd. is a biotechnology company that sprawls across the intricate landscape of genetic medicine, focusing tirelessly on harnessing the therapeutic potential of stereochemistry in designing drugs. Founded with an innovative spirit, the company has carved out a niche by developing stereopure oligonucleotides, which are synthetically crafted RNA or DNA molecules tailored to enhance therapeutic efficacy and safety. The precision and clarity with which WAVE defines each aspect of its drug candidates separate them from many competitors in the gene therapy arena. With their proprietary platform, PRISM, WAVE leverages a deep understanding of genetic and molecular nuances to address rare genetic diseases. Their pipeline is reflective of this targeted approach, with clinical trials and research focusing on conditions like Huntington's disease, Duchenne Muscular Dystrophy, and other inherited disorders that have limited treatment options.

The business model of WAVE revolves around both in-house development and strategic partnerships, driving revenue through research collaborations and potential milestone payments. By collaborating with larger pharmaceutical entities, WAVE amplifies its reach and resources, allowing it to tackle more complex challenges in genetic diseases. These partnerships are financially synergistic, enabling WAVE to continuously invest in its R&D efforts, which are pivotal for long-term growth and sustainability. The company’s focus on innovative medicines and the establishment of credible partnerships underscores its dual strategy of creating breakthrough treatments while maintaining a robust financial backbone, striving to transform the landscape of genetic therapies ethically and effectively.

Show more
Loading

Earnings Calls

2024 Q4
Feb 20, 2025
Show Transcript
Previous
Next
Hasbro's Growth Strategy Delivers Cost Savings and Revenue Guidance
2024 Q4
Feb 20, 2025

In 2024, Hasbro achieved $4.1 billion in revenue, down 7% but saw a 76% rise in adjusted operating profit to $838 million. Wizards grew 4% with a record margin of 41.8%. Cost control improved efficiencies, yielding $227 million in net savings to enhance dividends. Looking ahead, revenue is expected to rise slightly in 2025, with Wizards projected to grow 5-7%, while Consumer Products may decline up to 4%. The company targets $1 billion in savings by 2027, and overall revenue is projected to grow at a mid-single-digit CAGR through 2027.

Show Full Analysis

Management

Mr. Kyle B. Moran CFA
CFO & Principal Accounting Officer
No Bio Available
Dr. Erik Ingelsson M.D., Ph.D.
Chief Scientific Officer
No Bio Available
Ms. Kate Rausch
Head of Investor Relations
No Bio Available
Ms. Daryn Lewis
Senior VP & Head of Human Resources
No Bio Available
Dr. Sridhar Vaddeboina Ph.D.
Senior Vice President of Chemistry, Manufacturing & Controls
No Bio Available
Ms. Anne-Marie Li-Kwai-Cheung
Chief Development Officer
No Bio Available
Dr. Hsiu-Chiung Yang Ph.D.
Senior Vice President of Translational Medicine
No Bio Available

Contacts

Address
7 Straits View, #12-00, Marina One East Tower
Contacts